Video endoscopic camera/software from Kettex Development NO-STROBO
7-9.10.2021: We will exhibit at Czech/Slovak Days of Phoniatry in Bratislava.
8-11.9.2021: We will exhibit at Slovak National ENT conference in Zilina. Meet us there!
15.8.2021: We are proud to announce a new distributor of our devices in Poland - EUMed Sp.z o.o.
14.6.2021: A small step for a doctor, but a big step for our company. We sold our first camera in Belgium.
10.2.2021: We release a new camera KX-01-OR for operation theatre. It complies with MDR, of course.
5.10.2020: Our diagnostic camera KX-01 and our Software officially complies with MDR. It took us 14 months of work, but we made it.
We are producers of USB endoscopic cameras and software. Our cameras provide superb images and our software provides unique features.
The cameras and software comply with MDR.
For instant support please use chat icon in bottom-right corner.
With more complex questions please contact us by email.
We answer in 24 hours.
Kettex Development s.r.o.
Pod vodárenskou věží 4, Prague
Cell phone: +420 728 526 720
Lab report 3: NO-STROBO camera
We have developed a NO-STROBO camera system, which allows to capture motion of vocal chords without using stroboscopic light source. Ours system needs: still light source (eq. to 70W LED), our camera and our special NoStroboBlackBox(NSBB) device.
The size of the NSBB is 100x50x20mm.
The camera is originaly 2048x1536 pixels, and additional NSBB can be attached to our camera. Camera still have all the features described here and this feature is just added.
➙no blinking of the image
➙no additional light source -> cheaper solution, less space occupied
➙pitch detection tested from 90-500 Hz and works flawlesly in full range
➙pitch detected in 120 ms
➙NSBB will be very cost effective - we are targeting the price around 1000Euro for it
➙Lower resolution: 1024x768 with light equal to 70 Watt LED
We have the working prototype. Will be declared as MD class I under MDR (camera, blackbox, software), unofficialy EMC test passed. Will be released in H2 2021 for the market.